Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa; Retinitis Pigmentosa Syndrome Intervention: Drug: EA-2353 Sponsor: Endogena Therapeutics, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials